Osteosarcoma is the most common cause of cancer-associated mortality and the prognosis is yet to be fully elucidated due to the paucity of effective therapeutic targets that significantly influence the quality of life and mean survival rates of patients with osteosarcoma. Studies have showed that tripartite motif-containing (TRIM)-14 is a member of the TRIM protein family that has a vital role ...

Osteosarcoma is the most common malignant bone tumor in children and adolescents. This aggressive cancer mostly occurs in the long bones. Therefore, novel therapeutic approaches, such as biological therapies and gene therapy, are required to efficiently treat osteosarcoma. Capsaicin (trans‑8‑methyl‑N‑vanillyl‑6‑nonenamide) has been demonstrated to inhibit the growth of several types of cancer c...

Background: Cisplatin (CisPt) resistance is one of the major problems for the treatment of osteosarcoma. The natural compound sulforaphane (SFN) are reported to have antitumor activity in many cancers. However, its effect to influence CisPt resistance in osteosarcoma cells has not examined. In this study, we intended to investigate the combined effects of SFN and CisPt in osteosarcoma cells and...

Osterix is a novel zinc finger-containing transcription factor that is essential for osteoblast differentiation and bone formation. We hypothesized that osterix might have a role in osteosarcoma tumor growth and metastasis. Northern blot analysis showed that the mRNA level of osterix was decreased in two mouse osteosarcoma cell lines compared with its level in normal mouse osteoblasts. Osterix ...

Bone morphogenetic protein receptor 2 (BMPR2) has been identified in several types of cancer. However, its role in osteosarcoma is largely unknown. We systematically investigated the role of BMPR2 in osteosarcoma cell lines, human tissue samples and xenograft models. The relationship between BMPR2 expression and osteosarcoma patients' survival was investigated by bioinformatics and clinical dat...

To the Editor: We have read with great interest the article by Gu and coworkers reporting the coxsackievirus and adenovirus receptor (CAR) status on primary musculoskeletal tumors (1). We are particularly interested in their findings on osteosarcomas because we are developing gene therapy strategies for this cancer. CAR is the high-affinity viral receptor for most human adenovirus serotypes inc...

Osteosarcoma is a high-grade malignant bone tumor that manifests ingravescent clinical behavior. The intrinsic events that confer malignant properties on osteosarcoma cells have remained unclear, however. We previously established two lines of mouse osteosarcoma cells: AX cells, which are able to form tumors in syngeneic mice, and AXT cells, which were derived from such tumors and acquired an i...

The aim of this study was to uncover that unfolded protein response (UPR) contributed to the development of cisplatin resistance in osteosarcoma. MG-63 cells and SaOS-2 cells were exposed to cisplatin at presence or absence of 4-phenylbutyrayte (4-pba) and then analyzed by MTT assay and flow cytometry to determine the cell survival rates and apoptosis. Levels of glucose regulated protein 78KD (...

Conventional non-surgical therapeutic regimens against osteosarcoma are subject to chemoresistance and tumor relapse, and immunotherapy may be promising for this tumor. However, it's hard to find satisfactory epitopes for immunotherapy against osteosarcoma. Cancer/testis antigens (CTAs), such as MAGE-A family and NY-ESO-1, the potential antigens that almost exclusively express in tumor cells an...

Cabozantinib (CBZ) N-(4-((6,7-dimethoxyquinolin-4-yl) oxy) phenyl)-N-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide) (XL184), an inhibitor of MET and vascular endothelial growth factor receptor (VEGFR-2), is agent approved for the treatment several types carcinoma such as medullary thyroid renal. Recent studies are encouraging effectiveness CBZ in osteosarcoma. Because complex nature microenvi...